Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 23;5(2):22.
doi: 10.3390/pharmacy5020022.

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol

Sondra Davis  1 , Chad Friece  2 , Nicki Roderman  3 , Darrell Newcomer  4 , Evangelina Castaneda  5
Affiliations

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol

Sondra Davis et al. Pharmacy (Basel). .

Abstract

BACKGROUND: The primary purpose of this study is to determine whether insulin detemir is equivalent to insulin glargine in controlling hyperglycemia for the adult hospitalized patient on a basal-bolus treatment regimen. METHODS: A retrospective study was conducted at two acute care hospitals within the same health system. Patients from both facilities who were initiated on a basal-bolus subcutaneous insulin regimen were included in the study. The basal-bolus regimen consisted of three components: basal, bolus, and corrective insulin with only the data from the first seven days analyzed. Once the basal-bolus protocol was initiated, all previous glycemic agents were discontinued. The target glycemic goal of the study was 100-180 mg/dL. RESULTS: In both groups, 50% of the patients had achieved the target glycemic control goal (100-180 mg/dL) by day 2 (p = 0.3). However, on the seventh or last day of basal-bolus treatment, whichever came first, 36.36% of patients receiving insulin detemir (n = 88) achieved the blood glucose reading goal compared to 52.00% in patients receiving insulin glargine (n = 100) (p = 0.03). This corresponded to an adjusted odds ratio of 2.12 (1.08 to 4.15), p = 0.03. The adjusting variables were provider type, whether the patient was hospitalized within 30 days prior and diagnosis of stroke. The mean blood glucose readings for the insulin glargine and the insulin detemir groups while on basal-bolus therapy were 200 mg/dL and 215 mg/dL, respectively (p = 0.05). The total number of blood glucose readings less than 70 mg/dL and less than 45 mg/dL was very low and there were no differences in number of episodes with hypoglycemia between the two groups. CONCLUSION: There was not a statistical difference between the two groups at 2 days, however there was on the seventh day or the last day of basal-bolus treatment. There were nonsignificant hypoglycemia events between basal insulin groups and the results for the last or seventh day of treatment may not be clinically significant in practice.

Keywords: acute care; basal-bolus; hospital; inpatient; insulin detemir; insulin glargine; long-acting insulin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Blood glucose medications on discharge.
See this image and copyright information in PMC

References

    1. Davis E.M., Foral P.A., Dull R.B., Smith A.N. Review of Insulin Therapy and Pen Use in Hospitalized Patients. Hosp. Pharm. 2013;48:396–405. doi: 10.1310/hpj4805-396. - DOI - PMC - PubMed
    1. Dombrowski N.C., Karounos D.G. Pathophysiology and management strategies for hyperglycemia for patients with acute illness during and following a hospital stay. Metabolism. 2013;62:326–336. doi: 10.1016/j.metabol.2012.07.020. - DOI - PubMed
    1. Moghissi E.S., Korytkowski M.T., Dinardo M., Einhorn D., Hellman R., Hirsch I.B., Inzucchi S.E., Ismail-Beigi F., Kirkman M.S., et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. Diabetes Care. 2009;32:1119–1131. doi: 10.2337/dc09-9029. - DOI - PMC - PubMed
    1. American Diabetes Association Standards of Medical Care in Diabetesd—2016. Diabetes Care. 2016;39(Suppl. 1):S1–S2. - PubMed
    1. Handelsman Y., Bloomgarden Z.T., Grunberger G., Umpierrez G., Zimmerman R.S., Bailey T.S., Blonde L., Bray G.A., Cohen A.J., Dagogo-Jack S., et al. American Association of Clinical Endocrinologists and American College of Endocrinology-Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan-2015. Endocr. Pract. 2015;21(Suppl. 1):1–87. doi: 10.4158/EP15672.GLSUPPL. - DOI - PMC - PubMed

LinkOut - more resources